Roundtable Discussion: Triple Transfection, Transient Systems, or Stable Cell Lines – Which Pathway Best Supports Commercialization?
12:40 pm - Thursday 26th February 2026
- Comparing triple transfection and transient systems for their ability to rapidly support early-stage programs, while evaluating their scalability limits at clinical and commercial scales
- Exploring how plasmid-heavy approaches create supply challenges at large scale, and whether dual plasmid systems or stable cell lines can reduce dependency on GMP plasmid supply
- Debating which transfection or cell line strategy best supports PPQ runs, regulatory alignment, and robust COGs to ensure long-term viability of gene therapies
